Wall Street analysts expect that Revance Therapeutics Inc (NASDAQ:RVNC) will announce ($0.95) earnings per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Revance Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.90) and the lowest estimate coming in at ($0.98). Revance Therapeutics posted earnings of ($1.01) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.9%. The firm is scheduled to report its next quarterly earnings report on Thursday, November 1st.
According to Zacks, analysts expect that Revance Therapeutics will report full-year earnings of ($3.90) per share for the current financial year, with EPS estimates ranging from ($3.92) to ($3.89). For the next fiscal year, analysts expect that the company will post earnings of ($3.99) per share, with EPS estimates ranging from ($4.22) to ($3.71). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Revance Therapeutics.
Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.02). The business had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $0.93 million. Revance Therapeutics had a negative net margin of 13,690.62% and a negative return on equity of 63.30%.
A number of equities research analysts have recently commented on RVNC shares. Cantor Fitzgerald set a $50.00 price objective on Revance Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 2nd. Zacks Investment Research raised Revance Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research report on Wednesday, July 11th. BidaskClub raised Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 13th. Finally, ValuEngine raised Revance Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $47.10.
A number of hedge funds have recently bought and sold shares of the business. Sio Capital Management LLC purchased a new stake in Revance Therapeutics during the second quarter valued at about $2,780,000. MetLife Investment Advisors LLC grew its position in Revance Therapeutics by 41.5% during the second quarter. MetLife Investment Advisors LLC now owns 15,532 shares of the biopharmaceutical company’s stock valued at $426,000 after acquiring an additional 4,557 shares during the period. Metropolitan Life Insurance Co. NY grew its position in Revance Therapeutics by 25.8% during the second quarter. Metropolitan Life Insurance Co. NY now owns 10,875 shares of the biopharmaceutical company’s stock valued at $299,000 after acquiring an additional 2,232 shares during the period. Cubist Systematic Strategies LLC grew its position in Revance Therapeutics by 43.2% during the second quarter. Cubist Systematic Strategies LLC now owns 8,795 shares of the biopharmaceutical company’s stock valued at $241,000 after acquiring an additional 2,654 shares during the period. Finally, Bank of America Corp DE grew its position in Revance Therapeutics by 295.8% during the second quarter. Bank of America Corp DE now owns 120,757 shares of the biopharmaceutical company’s stock valued at $3,315,000 after acquiring an additional 90,248 shares during the period. 94.35% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:RVNC opened at $25.95 on Friday. The firm has a market capitalization of $991.78 million, a PE ratio of -6.47 and a beta of 1.28. Revance Therapeutics has a 52 week low of $23.35 and a 52 week high of $37.45.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.
Read More: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.